INTRODUCTION
The incidence of obesity and breast cancer has been continu ously increasing worldwide. Obesity is an important and modifiable risk factor for the development and progression of postmenopausal breast cancer [1] . An increase in breast can cer risk associated with higher body weight among postmeno pausal women has been attributed to elevations in circulating estrogen levels [2] . Although it is clear that estrogen plays an important role in various aspects of breast cancer develop ment, other factors which have been interested in proteins synthesized in adipose tissue, which may influence breast can cer development, can be involved [3, 4] . Leptin is one of these proteins and a 16kDa protein hormone product of the obese (ob) gene as well as a potent adipocytokine [5] . Leptin binds to the leptin receptor (ObR), belonging to the class I cytokine receptor superfamily, which activates the janus kinase signal transducer, an activator of transcription (JAK/STAT) and the Ras/extracellular signalregulated kinase (ERK1/2) signal transduction pathways [6] . A number of isoforms of ObR have been identified, but the long isoform (ObRb) has been noted to contain an active intracellular signaling domain and to have the ability to activate the intracellular JAK/STAT, Ras/ ERK1/2, and PI3KAktGSK3 pathways [7] . Short isoforms (ObRa) lacks major domains and mainly activate MAPK and have little effect on STAT activation [8] . In the breast, leptin is required for normal mammary gland development and lacta tion, however, leptin may also contribute to tumorigenesis in mammary tissue [9] . Several actions of leptin, including stim ulation of normal and tumor cell growth, cellular migration and invasion, and enhancement of angiogenesis, suggest that this hormone could promote an aggressive estrogenindepen dent breast cancer phenotype [10] . Recent studies have sug gested that the leptin and estrogen systems are involved in functional crosstalk. For instance, leptin has been shown to Purpose: Leptin is a potent adipokine that plays a significant role in tumor development and the progression of breast cancer. The aim of this study was to evaluate whether leptin affects the response to tamoxifen treatment in estrogen receptor (ER)-positive breast cancer cells. Methods: Leptin, leptin receptor (Ob-R), and activation of signaling pathways were studied by Western immunoblotting. The effects of leptin on tamoxifen-dependent growth inhibition were studied in MCF-7 and T-47D cells. Results: Leptin was expressed in MCF-7 and T-47D and had a proliferative effect on MCF-7 cells. Leptin significantly inhibited the antiestrogenic effect of tamoxifen in both cells only under β-estradiol (E2) (20 nM) conditions. In MCF-7, the inhibitory effect against tamoxifen was a result from the activation of the ERK1/2 and STAT3 signal transduction pathway. Conclusion: Leptin interferes with the effects of tamoxifen under E2 stimulated conditions in ER-positive breast cancer cells. These results imply that inhibition of leptin is expected to enhance the response to tamoxifen in ER-positive breast cancer cells, and, therefore, could be a promising way to overcome endocrine resistance.
modulate aromatase activity either in a positive or negative fashion [1114] . Furthermore, 17βestradiol (E2) has been shown to upregulate the synthesis of leptin mRNA and pro tein in adipocytes [15] . E2 can also modulate ObR expression [16] , possibly through a putative estrogen responsive element in the ObR gene promoter [17] . In MCF7 cells, leptin has been shown to induce aromatase gene expression, elevating aromatase activity and increasing estrogen synthesis [11] . Leptin has also been shown to enhance estrogen receptor α (ERα)-dependent transcription by decreasing ERα ubiqui tination and degradation, especially in the presence of the an tiestrogen ICI 182,780 [18] . Furthermore, leptin has been shown to transactivate ERα via the ERK1/2 pathway [19] . Therefore, we hypothesized that circulating leptin plays an important role in tumor development especially in ERposi tive breast cancer cells, which are known to have significant resistance to hormone therapy in ERpositive breast cancer. We studied the effect of leptin on the response to tamoxifen in ERpositive breast cancer cells and investigated changes in the activation of multiple leptin stimulated ObR signal transduc tion pathways.
METHODS

Cell culture and therapeutic agents
MCF10A, MCF7, MDAMB231, MDAMB453, and MDAMB468 cell lines were obtained from the American Type Culture Collection (Manassas, USA); T47D, HCC70, SKBR3, HCC1954, Hs578T, and HCC38 cell lines were ob tained from Korea Cell Bank (Seoul, Korea). MCF10A nor mal breast cell line was grown in DMEM/F12 (GibcoBRL, Gaithersburg, USA) media with 5% horse serum (Invitrogen, Cergy Pontoise, France), 1% penicillin/streptomycin (Gibco BRL), 0.5 μg/mL hydrocortisone (SigmaAldrich, St. Louis, USA), 100 ng/mL cholera toxin (SigmaAldrich), 10 μg/mL insulin (SigmaAldrich), and 20 ng/mL recombinant human EGF (Invitrogen). MDAMB231, MDAMB453, MDA MB468, and Hs578T cell lines were cultured in DMEM (Gib coBRL) with 10% fetal bovine serum (FBS; Hyclone Labs Inc., Logan, USA) and 1% penicillin/streptomycin (Sigma Aldrich). All other cell lines were grown in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin. Cells were main tained in a humidified atmosphere, 5% CO2 at 37°C. The cul ture medium was changed every 3 to 4 days. Recombinant human Leptin was purchased from PeproTech Inc. (Rocky Hill, USA), Tamoxifen and 17βE2 were purchased from SigmaAldrich and dissolved according to the manufacturer's instructions.
Charcoal-stripped FBS and cell stimulation
To remove endogenous steroid hormones from the serum in cell culture medium, we used dextrancoated charcoal strip ping FBS. Briefly, dextrancoated charcoal was prepared by stirring 2.5% (w/v) NoritA charcoal and dextran T70 (0.025% w/v) in PBS and then storing for 18 hours at 4°C. The solution was centrifuged to pellet the charcoal at 1,000 g for 5 minutes, and the supernatant was decanted and replaced with the same volume of FBS. The tube was vortexed to thoroughly mix the charcoal with the serum and then incubated for 12 hours at 4°C. The stripped serum was passed through a prefilter and a 0.45 micron filter before sterilizing through a 0.2 micron filter. MCF7 and T47D (hormone receptorpositive) cell lines were used in this study. Cell cultures were changed to phenolred free media containing 10% charcoalstripped FBS for 5 days prior to treatment. Cells were treated with 50 and 100 ng/mL leptin, 10 and 20 nM E2, and 10 and 20 µM tamoxifen. All ex periments were repeated 3 to 4 times.
Western blot analysis and antibodies
Cells were washed twice with PBS and then suspended in a total protein extraction kit (Intron Biotechnology, Seongnam, Korea) on ice for 15 minutes. Lysates were cleared by centrifu gation at 13,000 rpm for 20 minutes. Protein concentrations were measured with the Bradford assay using a BioRad Pro tein Assay kit (BioRad Laboratories, Hercules, USA) accord ing to the manufacturer's instructions. Equal amounts of cell lysates were separated by SDSPAGE gels, and then transferred onto PVDF membranes (ImmobilonP; Millipore, Billerica, USA). Blots were blocked with blocking buffer (5% nonfat dry milk in TBST) for 1 hour, followed by incubation overnight at 4°C with Leptin and ObR rabbit polyclonal and βactin mouse monoclonal IgG antibodies. Antibody against the ObR (SC 1834) was purchased from Santa Cruz Biotechnology (Santa Cruz, USA). Leptin (LSC25172) and βactin (AC15) anti bodies were purchased from LSBio (Seattle, USA) and Sigma (St. Louis, USA), respectively. The following antibodies were used to study leptin receptor signal transduction pathways: antiHsc70 mAb (Assay Designs, Ann Arbor, USA), anti ERK1/2 Thr Protein expression levels were quantified using ImageJ soft ware (National Institute of Health, Bethesda, USA) for the de tection of the intensity of protein bands. Blots were washed 3 times in TBST, and incubated with peroxidaseconjugated af finipure rabbit antimouse IgG (1:5,000 dilution; Jackson Im munoResearch, West Grove, USA) or peroxidaseconjugated affinipure mouse antirabbit IgG for 1 hour at room tempera ture. After washing with TBST 4 times for 5 minutes each, immunocomplexes were visualized by enhanced chemilumi nescence (Amersham Biosciences).
Cell proliferation assay
For cell proliferation assays, cells were harvested, counted and plated at 2500 MCF7 cells and 2000 T47D cells per well in 96well plates and placed in an incubator overnight. After wards, the cells were grown in serumfree medium for 18 hours, and then leptin and E2 were added according to the above mentioned concentrations followed by incubation for 24 hours. The cells were then treated with tamoxifen, and after 48 hours, cell viability was determined with the CellTiterGlo ® Luminescent Cell Viability Assay Kit (Promega, Madison, USA) following the manufacturer's protocol. Cell proliferation assays were performed at least 3 times for both cell lines.
Induction of cell signaling
MCF7 and T47D cells were synchronized in serumfree medium and then stimulated with estradiol 20 nM, leptin 50 ng/mL, and tamoxifen 10 µM. Stimulation of ObRb was as sessed at different time points from 5 minutes to 6 hours. Hsc70 was used as a loading control at each time point for both cell lines. Phosphorylated levels of ERK1/2, STAT3, p38 MAPK, and ERα were assessed by Western blotting using 25 µg of protein and specific antibodies.
Statistical analysis
Graphs were generated and quantitative results were com pared using paired Student's ttest with SigmaPlot ® (Statistical Solutions Ltd., Cork, Ireland). pvalues were twosided, and a p< 0.05 level of probability was accepted as being statistically significant .
RESULTS
Leptin and Ob-Rb expression in breast cancer cell lines
To study the effect of leptin on tamoxifen action, we first determined the expression level of leptin and ObR in various breast cancer cell lines. Leptin expression was found in MCF 7, T47D, MDAMB453, HCC70, and MDAMB468 cells. These results were confirmed by quantitative analysis using ImageJ densitometry ( Figure 1A) . Notably, leptin expression was increased in ERpositive breast cancer cell lines compared to other types of breast cancer cells. ObRb was detected in the MCF7, SKBR3, MDAMB453, and MDAMB231 cell 
Leptin enhances the proliferation of MCF-7 cells
For cellular proliferation experiments, we chose to use MCF7 and T47D cells because they had differential expres sion patterns. MCF7 cells have an ERpositive, leptinposi tive, and ObRbpositive expression profile, whereas T47D cells have an ERpositive, leptinpositive, and ObRbnegative expression profile. In the cell viability assay, E2 at 10 and 20 nM had a significant proliferative effect on MCF7 cells com pared to the respective E2 10 and 20 nM control treatments (p< 0.001). Leptin at 50 ng/mL had no proliferative effect on MCF7 cells (p= 0.211), however, there was a significant pro liferative effect of leptin at 100 ng/mL (p< 0.001) (Figure 2A ). In the T47D cell line ( Figure 2B ), E2 at 10 nM increased cell proliferation but was not statistically significant (p = 0.123). However, E2 at 20 nM had a significant proliferative effect compared to the control (p= 0.048). Leptin at 50 and 100 ng/ mL had no proliferative effect on T47D cells (p = 0.565 and p= 0.641, respectively). Tamoxifen at 10 and 20 µM had a sig nificant inhibitory effect on proliferation of both MCF7 and T47D cells in a dose dependent manner. However, leptin at 50 and 100 ng/mL had no additional proliferative effect on MCF7 cells compared to E2only treated control MCF7 cells under both E2 10 and 20 nM treatments. Leptin did not affect the activity of tamoxifen treatment compared to tamoxifen only treated control MCF7 cells. Similar results were obtained in T47D cells (data not shown). Thus, the results conclusively establish that leptin does not interfere with the effect of E2 or tamoxifen in either MCF7 or T47D cells.
Leptin inhibited the antiestrogenic effect of tamoxifen under E2 treated conditions
In MCF7 cells, leptin at 50 and 100 ng/mL had no signifi cant effect on tamoxifen response in E2 10 nM treated cells ( Figure 3A) . Interestingly, in E2 20 nM treated MCF7 cells ( Figure 3B ), leptin at 50 ng/mL had a significant inhibitory ef fect on the response to both 10 and 20 µM tamoxifen (p<0.001 and p<0.001, respectively). In T47D cells, when leptin 50 ng/ mL was added to the combination of E2 10 nM and tamoxi fen 10 μM, leptin significantly inhibited the antiestrogenic ef fect of tamoxifen (p= 0.037) ( Figure 3C ). Leptin at 50 ng/mL also had a significant inhibitory effect on tamoxifen response with E2 at 20 nM (p = 0.021) ( Figure 3D ). In cell signaling, when leptin was added to the combination treatment of E2 and tamoxifen, ERK1/2 and STAT3 were activated compared to the E2 and tamoxifen only combination at 1 hour in MCF 7 cells ( Figure 4A ). In contrast, in T47D cells, when leptin was added to the combination of E2 and tamoxifen, leptin did not have any effect on ERK1/2 and STAT3 signaling ( Figure  4B ). The p38 MAPK and ERα signal transduction pathways were not activated or altered by treatment with leptin in either MCF7 or T47D cells. 
DISCUSSION
The goal of hormone therapy is to block estrogeninduced proliferation of breast cancer cells. The ER is expressed in ap proximately 70% of patients with breast cancer. In spite of high levels of ER expression, many ERpositive patients dem onstrate resistance to hormone therapy. The ObR and ERα have been found to be coexpressed in malignant mammary tissue and in breast cancer cell lines [20] . Therefore, it is possi ble that the ObR and ERα signal transduction pathways are involved in functional crosstalk that contributes to tumor de velopment and progression. Leptin is also known to crosstalk with and transactivate several signal transduction pathways, including estrogen, the EGF receptor and HER2 signal trans duction pathways, that are targets of breast cancer therapy [21] . Therefore, we anticipated that leptin would play some role in resistance to antiestrogenic treatment, and our results showed that leptin inhibited the antiestrogenic effect of tamox ifen in MCF7 and T47D ERpositive breast cancer cells under E2 stimulation. This finding was supported by a recent study by Chen et al. [22] .
Leptin is known to activate the STAT3 signal transduction pathway in ERαpositive breast cancer cells which are already resistant to antihormones. Thus, high leptin levels in obese breast cancer patients may contribute to the development of antiestrogen resistance [23] . These results were confirmed by Figure 3 . Leptin inhibition of the antiestrogenic effect of tamoxifen under estradiol stimulated conditions in MCF-7 and T-47D cells. In MCF-7 cells with estradiol 10 nM stimulation, leptin had no effect on the activity of tamoxifen for each combination treatment (A). At estradiol 20 nM stimulation, when leptin 50 ng/mL was added to tamoxifen treatment, leptin significantly inhibited the 10 and 20 µM tamoxifen responses (B). In T-47D cells, leptin 50 ng/mL had an inhibitory effect on tamoxifen 10 µM with estradiol 10 and 20 nM (C and D, respectively). There was no significant difference between leptin 100 ng/mL treatment and no leptin treatment. With tamoxifen 20 µM, cell viability was notably decreased compared to tamoxifen 10 µM treatment, and there was no difference between each combination. All cell viability results are expressed by the ratio of comparison to control (no treatment) group. leptininduced activation of multiple signal transduction pathways in the current study. When leptin was added to E2 and tamoxifen combination treatment, remarkably, leptin ac tivated total and phosphoERK1/2, total and phospho STAT3 compared to E2 and tamoxifen combination alone in MCF7 cells ( Figure 4A ). These results suggest that leptin in hibits the antiestrogenic effect of tamoxifen under E2 stimula tion through activation of the ERK1/2 and STAT3 signal transduction pathways. In contrast to the results obtained in MCF7 cells, in ObRb negative T47D cells in which leptin also had an inhibitory effect on tamoxifen acitivity ( Figure 3C and 3D), the phosphoERK1/2 and phosphoSTAT3 signal transduction pathways were not activated but total ERK1/2 and total STAT3 were found to be activated ( Figure 4B ). These results suggest that leptin exerts its activity not only through the ObRb, but also through crosstalk with other signal transduction pathways implicated in tumorigenesis. A recent discovery revealed that ERα turnover is differentially regulat ed depending on whether the receptor is free (not bound by ligand), agonist bound, or antagonist bound and whether sig nal transduction pathways (e.g., MAP kinases) are induced by other cell surface receptors [24] . Thus, it is possible that leptin can exert its action only on antiestrogen ICI 182,780depen dent estrogen receptor processing. Indeed, in different assays, no effects of leptin were observed in the basal or E2induced activity of ERα [18] . This phenomenon was also shown in our study; leptin had no additional proliferative effect on E2only treatment in both MCF7 and T47D cells. However, in E2 and tamoxifen combination treatment, leptin showed an in hibitory effect on tamoxifen in both MCF7 (ObRb positive) and T47D (ObRb negative) cells. That is, leptin can exert its action only on tamoixifendependent ER processing, display ing its maximal activity at a concentration of 50 ng/mL.
Previous studies have demonstrated in vitro that leptin stimulates cancer cell proliferation [25] as well as inhibits apoptosis [26] and induces angiogenesis [27] . Leptin was re cently reported to stimulate the proliferation of various tumor cell types (prostate, colorectal, lung) [28] . Similar results have been described in breast cancer in which leptin was shown to stimulate the proliferation of various breast cancer cell lines [20] . Chen et al. [29] found no significant effect of surgical tu mor removal on high serum leptin concentrations in their breast cancer patients. This finding is consistent with the hy pothesis that production of leptin by tumor cells is a minor Figure 4 . Leptin activates multiple signal transduction pathways in MCF-7 cells compared to T-47D cells. MCF-7 and T-47D cells were synchronized in serum-free medium and then stimulated with estrogen (20 nM), leptin (50 ng/mL), and tamoxifen (10 µM). Stimulation of Ob-Rb was assessed at different time points from 5 minutes to 6 hours. Hsc70 was used as a loading control at each time point for both cell lines. Activation (phospho) and levels of ERK1/2, STAT3, p38 MAPK, and estrogen receptor α (ERα) were assessed by Western blotting in 25 µg of protein using specific antibodies. Figure 4 shows multiple signal transduction pathways being activated at 1 hour. Tamoxifen 10 µM effectively inhibited the activity of total-and phospho-ERK1/2 and STAT3 in both cell lines. (A) In MCF-7 cells, when leptin was added to the combination of estrogen and tamoxifen, leptin induced activation of total-and phospho-ERK1/2, total-and phospho-STAT3 signaling (grey box). There were no significant differences in total-and phosphop38 MAPK, and ERα signaling when leptin was added to the combination of estrogen and tamoxifen. (B) In contrast to the results obtained in MCF-7 cells, in T-47D cells, there was no activation of the phospho-ERK1/2 and phospho-STAT3 signal transduction pathways. Also, total-and phosphop38 MAPK, ERα signaling were not activated by addition of leptin (grey box). source of the adipokines, while unexcised adipose tissue re mains the major contributor to circulating levels of leptin [3] . Therefore, serum leptin levels are considered an important factor which affects the tumor environment in breast cancer [30] . In the current study, leptin significantly inhibited the anti estrogenic effect of tamoxifen in the presence of E2 in ER positive breast cancer cells. That is, increased serum leptin levels in breast cancer patients could be a cause of endocrine resistance, especially for those with high serum E2 levels. Therefore, inhibition of leptin, including lowering of circulat ing leptin levels, could be an effective measure to overcome hormone resistance as well as antitumor activity. Although largescale clinical studies are required to draw clinically meaningful conclusions, we found that leptin may be a prom ising target for the treatment of ERpositive breast cancer.
